Seizure Detection and Automatic Magnet Mode Performance Study

Epilepsy Clinical Trial

— E-36  

Official title:

Seizure Detection and Automatic Magnet Mode Performance Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01325623
• Other study ID #: Epilepsy (E)-36
• Status: Completed
• Phase: N/A
• First received: March 23, 2011
• Last updated: December 21, 2015
• Start date: March 2011
• Est. completion date: July 2015

Study information

• Verified date: December 2015
• Source: Cyberonics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health Products
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to confirm cardiac-based seizure detection in Cyberonics Model 106 VNS Therapy System.

Description:

Prospective, observational, unblinded, multi-site study designed to collect data on patients implanted with a Model 106 VNS Therapy System from baseline through an EMU stay of up to 5 days. After the EMU stay, patients will continue follow-up for safety for approximately two years or until final regulatory approval of the product.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: July 2015
• Est. primary completion date: July 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with a clinical diagnosis of medically refractory epilepsy dominated by partial seizures suitable for implantation with the Model 106 VNS Therapy System.

• Patients with a history of increased heart rate (tachycardia) associated with seizure onset based on clinical data obtained from medical history, admission/hospital charts, or prior neurophysiologic evaluations.

• Patients willing to undergo an EMU evaluation for a period of at least three days with activation of the AMM feature during that time.

• Patients having an average of = 3 seizures per month based upon diary or patient reporting for the 3 months prior to the screening visit.

• Patients must have peak-peak R-wave amplitude greater than or equal to 0.40 mV on ECG measured from the proposed electrode location in the neck to the proposed generator location in the chest via surface ECG electrodes in 7 different body positions.

• Patients must be at least 18 years old.

• Patients must be in good general health and ambulatory.

• Patient must be willing and able to complete informed consent.

Exclusion Criteria:

• Patients have had a bilateral or left cervical vagotomy.

• Patients currently use, or are expected to use, short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy.

• A VNS Therapy System implant would (in the investigator's judgment) pose an unacceptable surgical or medical risk for the patient.

• Patients expected to require full body magnetic resonance imaging.

• Patients have a history of VNS Therapy.

• Patients have a documented history of clinically meaningful bradycardia (heart rate less than 50 bpm) associated with seizures.

• Patients with a significant psychiatric disorder, significant cognitive impairment, history of major depression, or suicidality as defined by DSM IV-TR that in the investigator's judgment would pose an unacceptable risk for the patient or prevent the patient's successful completion of the study.

• Patients with a history of status epilepticus within 3 months of study enrollment.

• Patients prescribed drugs specifically for a cardiac or autonomic disorder that in the investigator's opinion would affect heart rate response unless the patient has ictal tachycardia while taking said drugs. These include, but are not limited to, beta adrenergic antagonists ("beta blockers").

• Patients with known clinically meaningful cardiovascular arrhythmias as well as patients with clinically meaningful cardiovascular arrhythmias determined by a 24-hour Holter recording obtained at the screening visit.

• Patients dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the past 2 years.

• Patients with a history of only psychogenic or pseudo seizures.

• Women who are pregnant. Women of childbearing age must take a pregnancy test.

• Patients currently enrolled in another investigational study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Epilepsy

Intervention

Device:
• Model 106 VNS Therapy System
The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.

Locations

Country	Name	City	State
Belgium	Hôpital Erasme	Anderlecht
Belgium	Cliniques Universitaires Saint-Luc	Brussels
Belgium	Universitair Ziekenhuis Gent	Ghent
Germany	Epilepsie-Zentrum Bethel	Bielefeld
Germany	Universitätsklinikum Bonn	Bonn
Germany	Universitätsklinikum Erlangen	Erlangen
Germany	Albert-Ludwigs-Universität	Freiburg
Germany	Ludwig-Maximilians-Universität München	Munich
Germany	Universitätsklinikum Tübingen	Tübingen
Netherlands	Kempenhaege	Heeze
Norway	Oslo University Hospital	Oslo
United Kingdom	King's College Hospital	London
United Kingdom	The National Hospital for Neurology and Neurosurgery	London
United Kingdom	Royal Hallamshire Hospital	Sheffield

Sponsors (2)

Lead Sponsor	Collaborator
Cyberonics, Inc.	PRA Health Sciences

Countries where clinical trial is conducted

Belgium,  Germany,  Netherlands,  Norway,  United Kingdom, 

References & Publications (1)

Boon P, Vonck K, van Rijckevorsel K, El Tahry R, Elger CE, Mullatti N, Schulze-Bonhage A, Wagner L, Diehl B, Hamer H, Reuber M, Kostov H, Legros B, Noachtar S, Weber YG, Coenen VA, Rooijakkers H, Schijns OE, Selway R, Van Roost D, Eggleston KS, Van Grunde — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Summary of Seizures Reported by Investigators and Triple Review	Subjects were admitted to the EMU and underwent standard continuous data collection of vEEG and ECG for 3 to 5 days. If a seizure occurred during the EMU stay, clinical investigators annotated the start and stop times, the type of seizure, the presumed seizure onset location, and the lobe of origin as applicable.; Following the EMU data collection phase of the trial, the de-identified, continuous electronic records (per patient) from the EMU period were provided to an independent and blinded triple review panel. This panel evaluated the EEG data and annotated seizure onset, seizure offset, and a description of seizure type. In the absence of video, seizure types could only be specified as: partial (particular type not denoted), generalized (non-absence), absence, or partial with secondary generalization.	Epilepsy Monitoring Unit Stay	No
Primary	Observed Sensitivity Based on Heart Rate Increase Associated With Seizures by Randomized SDA Setting	Sensitivity is the total number of seizures detected divided by the total number of seizures during EMU stay.Data used to support sensitivity analyses included digital ECG/EEG files,corresponding M106 device downloads,and CRF data.Seizure and non-seizure EEG segments were provided to independent reviewers to confirm seizure occurrence and define EEG seizure onset times.Seizure onset times were then compared with observed M106 device detections at the detection threshold setting for AutoStim that the patient was randomized to(SDA 2;60%,SDA 4;40%,SDA 6;20%).Sensitivity is only reported if the heart rate surpassed the programmed detection threshold.Number of participants is total number of subjects who had seizures during the EMU stay.; An "Ictal tachycardia Seizure" is a seizure with Ictal Heart rate >= 100 bpm & at least 55% increase, or 35 bpm increase from baseline) Bootstrap confidence intervals using 3000 bootstrap samples. n=total number of seizures; N= number of participants	Epilepsy Monitoring Unit (EMU) Stay	No
Primary	Modeled Sensitivity Based on Heart Rate Increase Associated With Seizures by SDA Setting Post-Processed Through Bench-top Device Simulant	Sensitivity is defined as the total number of seizures detected divided by the total number of seizures during the EMU stay. Data used to support sensitivity analyses included digital ECG/EEG files, corresponding M106 device downloads, and CRF data. Seizure onset times were compared with modeled M106 device detections at the least sensitive setting capable of detecting the seizure based on the corresponding change in heart rate. The participants' surface ECG data collected during the trial and passed through DMSDAT, a validated bench-top simulant of the Automatic Stimulation feature, was used to produce modeled results for each threshold for AutoStim setting (1;70%, 2;60%, 3;50%, 4;40%, 5;30% and 6;20%). Number of participants is total number of subjects who experienced seizures during the EMU stay.; Bootstrap confidence intervals using 3000 bootstrap samples.	Epilepsy Monitoring Unit (EMU) Stay	No
Primary	Potential False Positives Based on Heart Rate Increase Associated With Seizures by Randomized SDA Setting	Potential false positive rate is defined as the sum across all patients of the total number of potential false positive detections divided by the sum across all patients of the appropriate monitoring time during the EMU stay. Data used to support the potential false positive rate analyses included digital ECG/EEG files retrieved from the EMU evaluation, corresponding M106 device downloads, and triple review results of EEG recordings.; The evaluated EMU monitoring time includes a daily 3 minutes stepping exercise during which patients stepped up and down on a step stool at a submaximal effort leve.	Epilepsy Monitoring Unit (EMU) Stay	No
Secondary	Validation of Cardiac R-Wave Detection	Cardiac R-wave detection was evaluated against concurrent ECG data (i.e. detailed R-wave test) collected during implant, the first titration visit, at the beginning of the EMU stay, and at the 12 month visit. R-R intervals were calculated using detected R-waves from the Implantable Pulse Generator (IPG) and from a standard ECG monitor during a pre-specified time interval. A time series 10 seconds was recorded using the IPG SyncPulse feature. Simultaneously, a corresponding time series over the same interval was recorded using a standard ECG monitor. The total number of beats accurately detected in the entire study population is reported.	At Implant, First Titration Visit, Day 1 EMU and 12 Months	No
Secondary	Characterization of Latency Period: Analysis of Observed Latency for True Positive Detections by Randomized SDA Setting	Latency is defined as the time difference between SDA detection time and the annotated seizure onset time. The earliest SDA detection was considered for each seizure. Seizure onset times were compared with M106 device detections at the randomized SDA setting. Negative latencies indicate that the SDA detection preceded the seizure onset time. The median latency is presented for seizures which met the definition of ictal tachycardia as well as all seizure types and indicate the observed latency range.	Epilepsy Monitoring Unit (EMU) Stay	No
Secondary	Human Factors and Usability of the AspireSR® VNS Therapy® System.	Usability survey data were collected from all site personnel who used the handheld programmer to evaluate the usability of the AspireSR® VNS Therapy® System.The device usability survey contained 17 questions that measure usability on a five-point Likert scale ranging from "Extremely Difficult" (5) to "Extremely Easy" (1). Site personnel were asked to assess usability of the software features, instructions for use, training materials, and overall usability of the system at four different time points. The time points include implant/recovery and the end of EMU.; Usability was calculated as percentage of the users who found the usability of system to be "easy-2" or extremely easy-1".	At implant/recovery up to EMU Discharge (2 to 4 weeks)	No
Secondary	Changes From Baseline in Seizure Frequency	Seizure frequency was calculated at 3, 6, 12, 18 and 24 month follow-up visits based on seizure diary information and compared to baseline estimates. Response rate was computed and summarized for partial seizures (SPS, CPS and CPS with 2nd GTCs) and overall seizure types as the percentage of patients that achieved =50% seizure reduction per month from baseline by visit.	Up to 24 Month visit	No
Secondary	Changes in Seizure Severity Based on Physician Reported Questionnaire (NHS3)	Investigators completed the National Hospital Seizure Severity Scale (NHS3) questionnaire at screening, at the end of the EMU stay (provided a seizure occurred during the EMU stay), and at follow-up visits. Severity was evaluated by seizure type. The range of NHS3 scale is 1-27 with 1 being the least severe and 27 being the most severe.; Negative median value means improvement.	up to 24 Months Visit	No
Secondary	Changes in Seizures Severity, Intensity & Post-Ictal Recovery Based on Patient Completed Seizure Severity Questionnaire (SSQ)	Clinical outcomes such as seizure severity, intensity and post-ictal duration were also assessed during the long-term follow-up visits (3, 6, 12, 18 and 24 months) with patient reported questionnaires (SSQ; Seizure Severity Questionnaire). The range for SSQ (all sub-scores) is 1-7 with 1 being the least severe and 7 being the most severe.; Mean SSQ scores at 3, 6, 12, 18 and 24 months were compared to baseline. A change from baseline is calculated as baseline minus follow-up visit score to correspond to the Minimally Important Change (MIC) criteria as defined in the Scoring Scheme for SSQ v2. Questionnaire. Subscale scores were averaged to compute the SSQ Total Score	Up to 24 Month visit	No
Secondary	Proportion of Seizures Ending During Stimulation by Type	Clinical outcomes including seizure duration and cessation were assessed with vEEG during EMU stay. Number of seizures treated with Automatic Stimulation during EMU were evaluated. Of these seizures, those ending during the 60 second course of Automatic Stimulation were assessed and tabulated by seizure type.	Epilepsy Monitoring Unit (EMU) Stay	No
Secondary	Summary of Seizure Duration (Seconds) for All Seizure Types by Subgroup(ITT Population) (Only Seizures With Post Ictal Duration (Seconds) Annotated)	Seizure duration was calculated using historical EEG data from patients enrolled in the trial and compared to the duration of seizures that occurred during the study EMU stay. The seizure start and end times were determined via clinical observation and/or through an adjudication process with qualified EEG reviewers.	Historical Seizures and Seizures during Epilepsy Monitoring Unit Stay	No
Secondary	Summary of Post Ictal Duration (Seconds) for All Seizure Types (ITT Population) (Only Seizures With Post Ictal Duration (Seconds) Annotated)	Post-ictal duration was quantified by identifying the time at which the number of EEG channels within the 95% confidence interval of relative power reaches a number that is consistent with that during the pre-seizure period. This measure represents the amount of time required following a seizure until the EEG recovers to the pre-seizure state. It is used to objectively estimate patient recovery time. Historical seizures were baseline EEG recordings measured during monitoring prior to implantation. Post-ictal duration is only reported for seizures with Post Ictal Duration (seconds) annotated and >= 20% Heart Rate Rise	Historical Seizures and Seizures during Epilepsy Monitoring Unit Stay	No
Secondary	Changes in Quality of Life on Patient Reported Questionnaire (QOLIE-31-P)	Quality of life data was collected using patient-completed QOLIE-31-P surveys and compared between baseline and follow-up visits. The MIC score for each subscale defines the threshold for Minimally Important Change. If a score exceeds the MIC Score, the improvement from baseline is considered clinically significant. The range for QOLIE-31-P (all sub-scores) is 0-100 with higher scores reflecting greater well-being.Subscale scores were averaged to compute the QOLIE Total Score.	up to 24 Months Visit	No
Secondary	Overall Summary of Seizure Intensity by Subgroup	Quantitative evaluation of EEG was used to characterize the seizures that were treated with Automatic Stimulation. Intensity was evaluated by surveying the average power level from the 10-20 system EEG channel of maximum output during the course of the seizure. Intensity was only reported for seizures with intensity annotated and >= 20% Heart Rate Rise. The relative intensity was calculated by normalizing the power calculations to the pre-seizure state, and thus the reported changes are dimensionless. n= number of seizures	Historical Seizures and Seizures during Epilepsy Monitoing Unit Stay	No
Secondary	Post-stimulation Heart Rate Changes	During a 1 hour period during the EMU stay, the VNS Therapy device was programmed to normal mode stimulation ON time 30 seconds, OFF time 5 minutes. AutoStim and Magnet Mode were programmed OFF. In this hour, 10 to 11 normal mode stimulations can be expected. Around each of these stimulations, ECG data were collected to assess potential stimulation related heart rate changes (during stimulation, after stimulation and after black-out time). A black-out time is a period after stimulation during which no seizure detections can occur, to ensure that potential stimulation related heart rate changes were not seen as ictal tachycardia that would trigger false positive detection. During the trial, the black-out time was programmed to 30 seconds. The heart rate changes for all stimulations and all patients were averaged.	EMU stay	No